Patients Treated with ALL Therapy Inotuzumab Ozogamicin Report Better Quality of Life
May 25th 2018Patients with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) who were treated with inotuzumab ozogamicin (InO) indicated better quality of life, functioning, and symptom scores compared with patients receiving standard-of-care chemotherapies.
Read More